Department of Medical Laboratory Sciences, University of Nigeria, Enugu, Enugu State, Nigeria
 Commentary   
								
																A System Biology Perspective to Overcoming the Challenges of JAK Inhibition Mon Therapy for Myeloproliferative Neoplasms: An Overview 
																Author(s): Alphonsus Ogbonna Ogbuabor*, Peter Uwadiegwu Achukwu, Silas Anayo Ufelle and Daniel Chukwuemeka Ogbuabor             
								
																
						 The JAK-STAT pathway mediates signals that are involved in hematopoiesis. Aberrant JAK-STAT signaling has been identified in
  myeloproliferative neoplasm making the pathway a novel therapeutic target for myeloproliferative neoplasms through the application of
  JAK inhibitors. A major limitation to therapy with the current JAK inhibitors is a lack of selectivity which results in toxicity to patients. It is
  thought that increasing the selectivity of inhibitors will reduce toxicity observed with JAK inhibition therapy. System biology is a novel
  technology that holds great potentials for increasing the selectivity of JAK inhibitors. Its Application to drug designing can broaden the
  spectrum as well as repurpose the available JAK inhibitors for improved clinical outcome and possible cure for myeloproliferative neoplasms.
  This review presents an overview on the role of syste.. Read More»
						  
																DOI:
								10.37421/2165-7831.2021.11.260															  
Journal of Blood & Lymph received 443 citations as per Google Scholar report